Core Viewpoint - China's invasive brain-computer interface (BCI) devices are rapidly entering clinical trials, marking a significant advancement in the field and positioning China as the second country globally to reach this stage after the United States [1][3]. Group 1: Clinical Trials and Developments - The first prospective clinical trial of invasive BCI in China has been successfully conducted by the Chinese Academy of Sciences and Fudan University, meeting medical device registration standards [1]. - Several companies, including Shanghai Ladder Medical Technology, are developing BCI devices aimed at treating patients with motor function disorders, such as spinal cord injuries and amyotrophic lateral sclerosis [3][4]. - Ladder Medical's BCI system has shown promising results, allowing patients to perform tasks like playing chess and racing games after just 2-3 weeks of training [3]. Group 2: Patient Recruitment and Research - The clinical cohort study led by Fudan University and Beijing Xuanwu Hospital has begun patient recruitment to validate the efficacy and safety of invasive BCI treatment [3]. - Companies like Beijing Chip Intelligence and Hangzhou Jialiang Medical have also announced plans for clinical research on BCI devices [3][4]. Group 3: Patient Impact and Demand - There is a significant demand for BCI technology, with over a thousand requests from paralyzed patients seeking participation in clinical trials [6][7]. - The development of BCI devices is seen as a beacon of hope for approximately 4 million spinal cord injury patients in China [7]. Group 4: Technological Advancements - Jialiang Medical has completed nearly 100 clinical implants for epilepsy treatment, with plans to submit data for product approval [8]. - Brain Tiger Technology has developed a next-generation wireless BCI product, which has shown capabilities in controlling complex games and smart devices [8]. Group 5: Industry Challenges and Future Outlook - Experts emphasize that while progress has been made, there is still a considerable gap between China's BCI development and that of leading global competitors [9]. - Companies are advised to focus on long-term research collaboration rather than immediate profit from BCI product sales [9].

Core Viewpoint - China's invasive brain-computer interface (BCI) devices are rapidly entering clinical trials, marking a significant advancement in the field and positioning China as the second country globally to reach this stage after the United States [1][3]. Group 1: Clinical Trials and Developments - The first prospective clinical trial of invasive BCI in China has been successfully conducted by the Chinese Academy of Sciences and Fudan University, meeting medical device registration standards [1]. - The BCI technology primarily targets patients with motor function disorders, such as spinal cord injuries and amyotrophic lateral sclerosis (ALS) [4]. - Several companies, including Shanghai Ladder Medical Technology, Beijing Chip Intelligence, and Hangzhou Jialiang Medical, are developing BCI devices and have announced clinical research plans [4]. Group 2: Patient Outcomes and Training - Initial results from the first patient implanted with an invasive BCI showed that after 2-3 weeks of training, the patient could perform tasks like playing chess and racing games, achieving a level of control similar to that of a healthy individual [3]. - The BCI system allows for two modes: outputting information from the brain to control external devices and inputting information to the brain for sensory restoration [3]. Group 3: Future Prospects and Challenges - Companies have received thousands of requests from paralyzed patients seeking participation in clinical trials, indicating a high demand for BCI technology [6][8]. - The development of BCI devices for treating epilepsy is expected to progress more rapidly, with nearly 100 patients already implanted and data being prepared for product approval [8]. - Experts emphasize the importance of focusing on the effectiveness of BCI devices for patients rather than solely on rapid commercialization [9].

Group 1 - The core viewpoint of the articles highlights the rapid advancement of invasive brain-computer interface (BCI) technology in China, with successful clinical trials indicating significant progress in treating patients with motor function disorders [1][2][5] - The first prospective clinical trial of invasive BCI in China has been successfully conducted by a collaboration between the Chinese Academy of Sciences and Fudan University, marking China as the second country after the United States to enter this stage [1][2] - Companies such as Shanghai Ladder Medical Technology, Beijing Chip Intelligence, and Hangzhou Jialiang Medical are actively developing BCI devices and planning to enter clinical trials [1][2][3] Group 2 - Ladder Medical's invasive BCI system has shown promising results, allowing patients to perform tasks like playing chess and racing games after just 2-3 weeks of training [2] - The clinical research led by Shanghai Huashan Hospital and Beijing Xuanwu Hospital aims to validate the effectiveness and safety of invasive BCI treatment for motor function disorders [2][3] - The NEO device developed by Tsinghua University is set to enroll 30 to 50 patients for implantation by the end of the year, focusing on spinal cord injury patients [3] Group 3 - The development of BCI devices is driven by the need to address the challenges faced by approximately 4 million spinal cord injury patients in China [5] - Companies have received thousands of requests from paralyzed patients seeking participation in clinical trials, indicating a strong demand for BCI technology [5] - Jialiang Medical has completed nearly 100 clinical implantations for epilepsy treatment, with plans to submit data for product approval, showcasing the potential for faster clinical application compared to spinal cord injury treatments [5][6] Group 4 - The advancement of BCI technology is expected to lead to more miniaturized and intelligent devices, enhancing long-term disease treatment and control over external smart devices [6] - Companies like Brain Tiger Technology have successfully implanted BCI devices in epilepsy patients, enabling them to control games and smart home devices through thought [6] - The emphasis is on the effectiveness of BCI devices for patients rather than the speed of product development, with a focus on long-term collaboration and research [7]

Core Viewpoint - The article discusses the successful clinical trial of an invasive brain-computer interface (BCI) in China, marking a significant advancement in the field and positioning China as the second country globally to enter this stage after Neuralink. Group 1: Clinical Trial and Technology - The clinical trial was conducted by the Chinese Academy of Sciences in collaboration with Fudan University Huashan Hospital and related enterprises [2] - The trial involved a 37-year-old male who, after a severe accident leading to limb loss, can now control a computer interface using only his thoughts [27][28] - The implanted neural electrodes are the smallest and most flexible globally, with a size comparable to a coin and a flexibility exceeding that of Neuralink's products by over 100 times [4][12][10] Group 2: Technical Innovations - The team utilized semiconductor processing technology to minimize damage to brain tissue, achieving a design that is both small and soft [8][15] - The new neural electrodes have a cross-sectional area that is 1/5 to 1/7 of Neuralink's electrodes, ensuring long-term stability and functionality [10][21] - The device has a projected lifespan of 5 years, with the potential for upgrades through secondary surgeries [22][33] Group 3: Future Applications - Short-term goals include enabling users to control robotic arms for physical tasks like grasping and holding objects [6][7] - Long-term aspirations involve controlling complex physical devices, such as robotic dogs and intelligent robots, thereby expanding the boundaries of daily life [7] - The research aims to significantly improve the quality of life for individuals with complete spinal cord injuries, amputations, and amyotrophic lateral sclerosis [34]

一水 发自 凹非寺 量子位 | 公众号 QbitAI 用意念操控万物的"脑机接口"，就这样离我们更近了？！ 据央妈最新报道， 我国已成功开展首例侵入式脑机接口临床试验 —— 一位因意外事故导致四肢截肢的男子，现在 仅凭意念 就能玩五子棋游戏、发短信等等。 这项研究由中国科学院脑科学与智能技术卓越创新中心，联合复旦大学附属华山医院以及相关企业合作完成。 其成功标志着，除了马斯克的Neuralink，我国成为 全球第二个 进入侵入式脑机接口技术临床试验阶段的国家。 而且所植入的神经电极目前全球尺寸最小、柔性最强—— 植入体仅硬币大小 （为Neuralink产品1/2） ，超柔性电极约为头发丝的1/100 （超过Neuralink百倍） 。 长期还可能涉及对复杂物理外设进行控制，例如对机器狗、具身智能机器人等智能设备的控制，拓展生活边界。 而以上这些目标的实现，均离不开团队在脑机接口 软硬件方面所取得的突破 —— 用上了半导体加工工艺 作为一种侵入式脑机接口 （需要通过微创手术将电极植入大脑） ，团队在硬件设计上核心追求一个目标： 最大程度降低对脑组织的损伤 。 对于这一新进展，网友们除了纷纷感叹科幻照进现实，更有 ...

Core Insights - The first invasive brain-computer interface (BCI) clinical trial in China is transforming the life of its subject, allowing him to control games using his thoughts, achieving efficiency comparable to that of a typical user with a touchpad [1] - China has become the second country globally, after the United States, to conduct invasive BCI clinical trials, with several metrics surpassing those of Neuralink, founded by Elon Musk [1][2] - The research is a collaboration between the Shanghai Institute of Neuroscience and Fudan University Huashan Hospital, contributing to Shanghai's goal of becoming a global technology innovation hub [1] Technology Comparison - The Shanghai BCI technology features ultra-thin and flexible electrodes, measuring only 1/5 to 1/7 the size of those used by Neuralink, significantly reducing damage to brain tissue [2] - The implanted device is the smallest globally, with a diameter of 26mm and a thickness of less than 6mm, which is half the size of Neuralink's product [2] Surgical Procedure - The surgical procedure for the invasive BCI is less invasive than Neuralink's, requiring only a small groove in the skull rather than penetrating it, making it more patient-friendly [3] Research and Development - The BCI research is led by young scientists who have returned to China, highlighting the importance of domestic talent in advancing this technology [4][5] - The Shanghai Institute has established a micro-nano electronic processing platform, enabling precise fabrication of BCI devices and accelerating research progress [6] Future Developments - The next version of the BCI system, expected by the end of this year or early next year, will feature 256 information transmission channels, four times the current capacity, and a smaller size [7] - Future applications aim to enhance motor control for paralyzed patients and potentially restore speech for those with language impairments [7] Industry Vision - The BCI technology is seen as a foundational technology for human enhancement and human-machine integration, with aspirations for consumer-level applications in the future [8] - Shanghai's "Future Industry Cultivation Action Plan" aims to establish a global innovation hub for BCI products by 2030, reflecting a clear vision for the industry's growth [8]

Core Insights - Neuralink has successfully enabled a monkey to "see" virtual objects through its brain-machine interface technology, which has potential applications for helping blind individuals perceive the world [1] - The device, named Blindsight, stimulates areas of the brain associated with vision, tricking the monkey's visual system into recognizing non-existent objects [1] - This marks the first public demonstration of Blindsight's experimental results, highlighting the cutting-edge nature of brain device development aimed at treating traditionally difficult medical conditions like blindness [1] Summary by Sections Technology and Innovation - Blindsight is a brain-implanted chip designed to simulate eye functions and directly stimulate the visual cortex [1] - During experiments, the monkey looked at the location of a virtual object over two-thirds of the time, indicating it perceived the non-existent target [1] Future Applications - The short-term goal of Blindsight is to assist blind individuals in seeing, while the long-term vision includes achieving "superhuman vision," such as the ability to see infrared light [2] - Neuralink is also advancing another project aimed at helping paralyzed individuals interact with computers using their thoughts [2] Human Trials - Currently, five humans have received Neuralink implants, with three implanted in 2024 and two in 2025, and some participants reportedly use the brain-machine device for up to 60 hours per week [2]

Core Viewpoint - The article highlights the successful initiation of China's first invasive brain-computer interface (BCI) clinical trial, marking a significant advancement in the field and positioning China as the second country globally to enter this phase after the United States [1]. Group 1: Clinical Trial and Patient Outcomes - The clinical trial involves a male subject who lost all four limbs due to an electric shock accident. Since the implantation of the BCI device in March 2025, the system has operated stably without infections or electrode failures for over a month. The subject achieved functionalities such as playing chess and racing games within 2-3 weeks of training, demonstrating control comparable to that of a typical user with a computer touchpad [1]. - The BCI system is expected to significantly improve the quality of life for patients with complete spinal cord injuries, double upper limb amputations, and amyotrophic lateral sclerosis once it receives approval for registration and market launch [1]. Group 2: Technological Advancements - The BCI system developed by the research teams is noted for having the smallest and most flexible neural electrodes globally, with a cross-sectional area only 1/5 to 1/7 that of Neuralink's electrodes. This design minimizes damage to brain tissue and enhances compatibility with neural interfaces [2]. - The system is the only one in China to have received a registration-type inspection report and can stably collect single-neuron spike signals, providing a solid data foundation for applications [3]. Group 3: Surgical and Operational Efficiency - The implanted device has a diameter of 26mm and a thickness of less than 6mm, making it the smallest brain-controlled implant globally, only half the size of Neuralink's product. This allows for a less invasive surgical procedure, reducing risks and recovery time [3]. - The design of the BCI system is based on principles of neuroscience, allowing for similar control levels to Neuralink with fewer implanted electrodes, thus minimizing patient risk [4]. Group 4: Future Applications - Following successful trials in non-human primates, the project team aims to enable the subject to control a robotic arm for physical tasks such as grasping and holding objects. Future developments may include controlling complex physical devices like robotic dogs and intelligent agents, thereby expanding the subject's capabilities in daily life [4].

Core Viewpoint - The article highlights the successful implementation of China's first invasive brain-computer interface (BCI) clinical trial, marking the country as the second globally to enter this phase of BCI technology [1][3]. Group 1: Clinical Trial Details - The subject of the trial is a male who lost all four limbs due to an electric shock accident. Since the implantation of the BCI device in March 2025, he has achieved functionalities such as playing chess and racing games within 2-3 weeks of training, reaching a level comparable to that of an average person using a computer touchpad [3]. - The BCI system aims to improve the quality of life for patients with spinal cord injuries and amputations through motor function replacement technology [3]. Group 2: Technological Innovations - The neural electrodes developed by the Chinese Academy of Sciences are the smallest and most flexible in the world, with a cross-sectional area only 1/5 to 1/7 of those used by Neuralink, and flexibility exceeding theirs by over a hundred times, minimizing damage to brain tissue [7]. - The BCI implant has a diameter of 26mm and a thickness of less than 6mm, making it the smallest brain-controlled implant globally, about half the size of Neuralink's product. This allows for a less invasive surgical procedure, reducing risks and recovery time [10]. Group 3: Surgical Precision - The success of the surgery relies on precise localization and implantation of the electrodes. Various brain function localization methods were employed, including functional MRI and 3D modeling, to create a detailed functional map of the patient's motor cortex, ensuring accurate implantation [11]. Group 4: Future Applications - The project team plans to enable the subject to use a robotic arm for physical tasks such as grasping and holding objects. Future developments will also include controlling complex physical devices like robotic dogs and intelligent agents to further expand the subject's capabilities [12].

Core Insights - The article highlights the successful initiation of China's first invasive brain-computer interface (BCI) clinical trial, marking a significant advancement in the field, making China the second country after the United States to enter this phase [1] Group 1: Clinical Trial Details - The clinical trial was conducted by the Chinese Academy of Sciences' Brain Science and Intelligent Technology Center in collaboration with Fudan University Huashan Hospital, focusing on a male subject who lost all four limbs due to an electrical accident [1] - The implanted BCI device has shown stable operation since its implantation in March 2025, with no infections or electrode failures reported over a month [1] - The subject achieved functionalities such as playing chess and racing games within 2-3 weeks of training, demonstrating control comparable to that of a typical user with a computer touchpad [1] Group 2: Technological Advancements - The BCI system developed by the Zhao Zhengtuo and Li Xue teams features the world's smallest and most flexible neural electrodes, with a cross-sectional area only 1/5 to 1/7 that of Neuralink's electrodes, and flexibility exceeding Neuralink's by a factor of 100 [2] - This ultra-flexible electrode allows for high-density, large-area, and long-term stable neural signal acquisition, addressing key challenges in tissue compatibility and bandwidth limitations for implanted BCIs [2] Group 3: Surgical and Operational Efficiency - The BCI system is the only one in China with a registered report that can stably capture single-neuron spike signals, providing a solid data foundation for applications [3] - The device's dimensions are 26mm in diameter and less than 6mm in thickness, making it the smallest brain-controlled implant globally, requiring only a small recess in the skull for implantation, thus reducing surgical risks and recovery time [3] - The standardized operational procedures based on mature surgical techniques facilitate scalable applications in various medical institutions [3] Group 4: Future Applications - The BCI system is designed to achieve similar control levels as Neuralink with fewer implanted electrodes, minimizing patient risk while maximizing benefits [5] - Prior to human trials, the system's safety and functionality were validated in non-human primates, where it successfully controlled computer cursor movement through neural activity [5] - Future plans include enabling the subject to control robotic arms for physical tasks, expanding the potential for interaction with complex devices like robotic dogs and intelligent agents [5]